StockData

Ensysce Biosciences vs Lipocine

ENSC and LPCN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ENSC and LPCN compare

Lipocine is the larger company, worth 1.8 times as much as Ensysce Biosciences ($13.2M against $7.5M).

Ensysce Biosciences grew revenue faster over the last twelve months (−39.3% versus −62.7% for Lipocine).

Lipocine scores higher on the StockData Score (9 against 5 for Ensysce Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricENSCLPCN
Size and price
Market cap$7.5M$13.2M
Share price$0.384$1.60
Change, 1 year−81.4%−44.3%
Change, 5 years−100.0%−91.7%
Beta (5Y)3.77−0.38
Employees814
StockData Score
Total score59 (better)
Valuation score13 (better)
Growth score11
Performance score00
Health score35 (better)
Dividend score00
Valuation
P/S1.7× (better)8.4×
P/B–0.6×
Fair value–$2.64
Margin of safety–39.3%
Growth
Revenue growth (TTM)−39.3% (better)−62.7%
Revenue growth, 5Y average5.2%–
Profitability
Operating margin−281% (better)−801%
Net margin–−755%
Return on equity–−60.9%
Financial health
Debt / equity–0.00
Interest coverage−791.6×–
Current ratio0.7011.48 (better)
Altman Z-score−81.05−9.43 (better)
Piotroski F-score–1
Dividends and buybacks
Buyback yield–−123%
Shareholder yield0.00% (better)−123%
Ownership
Held by institutions4.7%36.2%
Held by insiders6.2%9.0%
Insider net buying, 12 months$444K$596K (better)
Short interest, % of float0.49%4.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.